Evolving Best Practice: Individualizing Therapy in Severe Asthma – CME Activity
Dr. Njira Lugogo discusses the use of biologic agents in severe asthma, reviewing the approach to management, biomarker use, and specific inflammatory cascade targets. A discussion of real-world trial data in addition to extension study data underscores the effectiveness of biologic agents in reducing exacerbation, which raises the questions for some patients, is asthma remission possible, and what does it look like? Earn 1.00 CME/CE Credit.
Educational Objectives
At the conclusion of this activity, participants should be better able to:
- Discuss the relationship between pathophysiology, phenotypes/endotypes, and biological agent treatment targets in asthma
- Review emerging data, including real-world and long-term extension studies, on biologic treatments for patients with severe asthma
- Individualize biologic therapy selection for patients with severe asthma based on phenotype, comorbidities, and patient preferences
